scPharmaceuticals

scPharmaceuticals Inc. reported $10.0 million in product revenues, a net loss of $(35.1) million, and a loss from operations of $(18.1) million for Q3 2024. The company is focused on optimizing infused therapies, with FUROSCIX expanding to NYHA Class IV heart failure and a new autoinjector in development. The FDA awarded 3-year exclusivity to FUROSCIX, and the company estimates a $12.5 billion market for the product. The company expects continued net losses and is managing capital through various agreements and offerings.

DelveInsight's report on Congestive Heart Failure Market (2020-2034) covers epidemiology, market trends, key companies, and therapies. Market size was ~USD 6,900 million in 2023, expected to grow significantly. Key companies include Novartis, Bayer, and Eli Lilly. Therapies like ENTRESTO and JARDIANCE are highlighted. Market drivers include aging population and disease prevalence, while barriers include generic therapies and diagnostic challenges.

The ALLEVIATE-HF trial found that linking medical interventions to cardiac monitoring for high-risk heart failure patients was safe, with no serious adverse events. The intervention, involving diuretic uptitration triggered by high-risk alerts from subcutaneous insertable cardiac monitors (ICMs), resolved symptoms in 80% of symptomatic cases and prevented symptoms in 93% of asymptomatic patients. The study's phase 2 aims to assess the intervention's effectiveness in improving heart failure outcomes.

scPharmaceuticals announces FDA approval of sNDA expanding Furoscix indication in heart failure, now including NYHA Class IV patients.